Daily Judi: Friday, September 30, 2022
Every day we scan the headlines for the best items that engage the clinical trial ecosystem, workflow solutions, and more—all the latest news you need to know. Here are today's stories:
Writing for the Atlantic, Ed Yong explores the effects of long COVID on those with the complicated disorder, chronic fatigue syndrome, and the clinicians who advocate for patients with the illness.
Yesterday, the Food and Drug Administration approved AMX0035, a new drug for ALS, developed by Massachusetts-based Amylyx Pharmaceuticals. Amylyx’s research funding was partially raised through the viral social media campaign, “Ice Bucket Challenge.” (Biopharma Dive)
In August, Duke University School of Medicine staff volunteered to organize the 11th annual Pompe Patient Meeting, in Durham, NC. Also known as Glycogen Storage Disease Type II, Pompe disease is an inherited disorder that affects about one in 40,000 people in the United States. Duke is involved in clinical trials to introduce gene therapy as a treatment option for Pompe disease. (Magnify)
The CNS Summit 2022 will be held on November 17–20, in Boca Raton, Florida. Created as "a community of innovators and industry leaders who are not afraid to challenge the status quo," CNS was founded in 2009 to advance clinical development, focused on collaboration and innovation. Team Judi will be there!
“I work mainly with one CRO, and they thank us for being proactive, and for our precise attention. We get a lot of appreciation from their whole team as we help them with their deliverable.”
–Jess, Program Manager
Judi empowers and enhances the world's clinical trial ecosystems. Our cloud-based platform has 120,000 users across 168 countries. We eliminate the chaos so clinical teams can focus on the patient, rather than the process. We are a SOC 2 Type II certified collaboration platform.